|
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
RECRUITINGN/ASponsored by University Hospital, Bordeaux
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Bordeaux
Started2021-09-30
Est. completion2026-09
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT04798651
Summary
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * male or female subjects ; * Age ≥ 18 years; * subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome; * patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose; * affiliated to an health insurance system; * and who agree to participate in the study. Exclusion Criteria: * Pregnant or breastfeeding women, * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Conditions2
Clinically Isolated SyndromeMultiple Sclerosis
Interventions2
Related trials
- Angiogenic Biomarkers in Juvenile Idiopathic Arthritis — Assistance Publique - Hôpitaux de Paris
- Basal Plasma Lithium Levels and Suicidal Events — University Hospital, Montpellier
- Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects — Institut National de la Santé Et de la Recherche Médicale, France
- Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia — Centre Hospitalier Universitaire, Amiens
- Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas — Assistance Publique Hopitaux De Marseille
- Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial — Centre Hospitalier Universitaire, Amiens
- Creation of a French South-Eastern Database and DNA-bank of Congenital Heart Disease to Explore the Genetic Pathways — Assistance Publique Hopitaux De Marseille
- Detection of ISUP≥2 Prostate Cancers Using Multiparametric MRI: Prospective Multicenter Comparison of the PI-RADS Score and an Artificial Intelligence System — Hospices Civils de Lyon
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Bordeaux
Started2021-09-30
Est. completion2026-09
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT04798651